BioVie (BIVI) Competitors $1.03 +0.03 (+3.00%) Closing price 04:00 PM EasternExtended Trading$1.03 0.00 (0.00%) As of 06:42 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsHeadlinesInsider TradesOwnershipSEC FilingsShort InterestTrendsBuy This Stock BIVI vs. CRVO, PYXS, TELO, EPIX, JSPR, ADAP, IMAB, STRO, IGMS, and ZURAShould you be buying BioVie stock or one of its competitors? The main competitors of BioVie include CervoMed (CRVO), Pyxis Oncology (PYXS), Telomir Pharmaceuticals (TELO), ESSA Pharma (EPIX), Jasper Therapeutics (JSPR), Adaptimmune Therapeutics (ADAP), I-Mab (IMAB), Sutro Biopharma (STRO), IGM Biosciences (IGMS), and Zura Bio (ZURA). These companies are all part of the "pharmaceutical products" industry. BioVie vs. CervoMed Pyxis Oncology Telomir Pharmaceuticals ESSA Pharma Jasper Therapeutics Adaptimmune Therapeutics I-Mab Sutro Biopharma IGM Biosciences Zura Bio CervoMed (NASDAQ:CRVO) and BioVie (NASDAQ:BIVI) are both small-cap medical companies, but which is the superior stock? We will compare the two businesses based on the strength of their analyst recommendations, community ranking, dividends, valuation, institutional ownership, earnings, media sentiment, profitability and risk. Which has preferable valuation & earnings, CRVO or BIVI? CervoMed has higher revenue and earnings than BioVie. CervoMed is trading at a lower price-to-earnings ratio than BioVie, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioCervoMed$7.14M10.26-$2.17M-$2.18-3.86BioVieN/AN/A-$32.12M-$7.91-0.13 Which has more risk & volatility, CRVO or BIVI? CervoMed has a beta of -0.23, indicating that its share price is 123% less volatile than the S&P 500. Comparatively, BioVie has a beta of 0.66, indicating that its share price is 34% less volatile than the S&P 500. Do institutionals & insiders believe in CRVO or BIVI? 25.1% of CervoMed shares are owned by institutional investors. Comparatively, 4.6% of BioVie shares are owned by institutional investors. 35.4% of CervoMed shares are owned by company insiders. Comparatively, 4.0% of BioVie shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock is poised for long-term growth. Does the media favor CRVO or BIVI? In the previous week, CervoMed had 6 more articles in the media than BioVie. MarketBeat recorded 10 mentions for CervoMed and 4 mentions for BioVie. BioVie's average media sentiment score of 0.81 beat CervoMed's score of 0.32 indicating that BioVie is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment CervoMed 0 Very Positive mention(s) 1 Positive mention(s) 1 Neutral mention(s) 1 Negative mention(s) 0 Very Negative mention(s) Neutral BioVie 0 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Do analysts rate CRVO or BIVI? CervoMed presently has a consensus price target of $27.63, suggesting a potential upside of 228.09%. BioVie has a consensus price target of $3.00, suggesting a potential upside of 191.26%. Given CervoMed's higher possible upside, equities analysts plainly believe CervoMed is more favorable than BioVie.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score CervoMed 1 Sell rating(s) 1 Hold rating(s) 5 Buy rating(s) 2 Strong Buy rating(s) 2.89BioVie 0 Sell rating(s) 0 Hold rating(s) 1 Buy rating(s) 1 Strong Buy rating(s) 3.50 Is CRVO or BIVI more profitable? BioVie has a net margin of 0.00% compared to CervoMed's net margin of -118.68%. CervoMed's return on equity of -44.11% beat BioVie's return on equity.Company Net Margins Return on Equity Return on Assets CervoMed-118.68% -44.11% -39.81% BioVie N/A -134.07%-93.44% Does the MarketBeat Community believe in CRVO or BIVI? CervoMed received 7 more outperform votes than BioVie when rated by MarketBeat users. Likewise, 80.65% of users gave CervoMed an outperform vote while only 66.67% of users gave BioVie an outperform vote. CompanyUnderperformOutperformCervoMedOutperform Votes2580.65% Underperform Votes619.35%BioVieOutperform Votes1866.67% Underperform Votes933.33% SummaryCervoMed beats BioVie on 13 of the 18 factors compared between the two stocks. Get BioVie News Delivered to You Automatically Sign up to receive the latest news and ratings for BIVI and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart BIVI vs. The Competition Export to ExcelMetricBioViePharmaceutical IndustryMedical SectorNASDAQ ExchangeMarket Cap$19.12M$6.48B$5.33B$8.39BDividend YieldN/A2.64%5.21%4.11%P/E Ratio-0.119.0626.7119.71Price / SalesN/A251.48386.12120.59Price / CashN/A65.8538.2534.62Price / Book0.416.456.774.50Net Income-$32.12M$143.98M$3.23B$248.22M7 Day Performance-1.90%2.41%1.80%0.56%1 Month Performance25.63%4.56%11.10%13.17%1 Year Performance112.72%-2.67%17.11%7.30% BioVie Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)BIVIBioVie2.706 of 5 stars$1.03+3.0%$3.00+191.3%+106.7%$19.12MN/A-0.1110Gap UpCRVOCervoMed3.3212 of 5 stars$8.79+0.1%$27.63+214.3%-56.2%$76.50M$7.14M-4.034PYXSPyxis Oncology1.4278 of 5 stars$1.23+1.7%$9.00+631.7%-71.3%$76.20M$16.15M-1.1960Trending NewsEarnings ReportAnalyst ForecastAnalyst RevisionGap DownTELOTelomir Pharmaceuticals1.6442 of 5 stars$2.54+1.6%$15.00+490.6%-62.6%$75.60MN/A-4.381News CoverageEPIXESSA Pharma2.005 of 5 stars$1.70-0.6%$2.00+17.6%-73.2%$75.46MN/A-2.4650Positive NewsJSPRJasper Therapeutics2.1592 of 5 stars$5.02+1.8%$62.22+1,139.5%-79.1%$75.41MN/A-1.0620ADAPAdaptimmune Therapeutics2.7384 of 5 stars$0.29+4.8%$1.52+421.2%-74.5%$74.93M$178.03M-1.32490IMABI-Mab3.1956 of 5 stars$0.91+1.2%$5.50+503.8%-46.4%$74.24M$3.27M0.00380News CoveragePositive NewsSTROSutro Biopharma4.3863 of 5 stars$0.88-3.7%$6.11+596.2%-81.5%$74.18M$66.43M-0.55240News CoverageAnalyst ForecastIGMSIGM Biosciences4.2762 of 5 stars$1.24+5.1%$5.50+343.5%-86.0%$74.12M$2.68M-0.34190Positive NewsZURAZura Bio2.849 of 5 stars$1.08-2.7%$14.33+1,227.2%-81.3%$73.85MN/A-1.543News CoverageAnalyst Revision Related Companies and Tools Related Companies CervoMed Competitors Pyxis Oncology Competitors Telomir Pharmaceuticals Competitors ESSA Pharma Competitors Jasper Therapeutics Competitors Adaptimmune Therapeutics Competitors I-Mab Competitors Sutro Biopharma Competitors IGM Biosciences Competitors Zura Bio Competitors Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:BIVI) was last updated on 5/22/2025 by MarketBeat.com Staff From Our PartnersWhite House to reset Social Security?Elon Musk's parting DOGE gift looks set to shock America... A single announcement by July 22nd could soon b...Altimetry | SponsoredElon just did WHAT!?As you may recall, Biden and the Fed were working on a central bank digital currency, or CBDC. Had they got...Brownstone Research | SponsoredTrump Predicts Dollar DownfallREAD THIS VERY CAREFULLY: If you have $100,000 or more saved for retirement, this may make you VERY angry... ...Augusta Precious Metals | SponsoredThe Secret Map of America, Declassified…Locked inside a Maryland man’s private safe is a map. But not just any map, mind you… This map shows a “...Banyan Hill Publishing | SponsoredThe Robotics Revolution has arrived … and one $7 stock could take off as a result.Robots aren't coming to America in 2025. They are already here. Oxford Economics says, "The Robotics Rev...Weiss Ratings | SponsoredElon’s backup plan for AIElon knows the future isn’t about smarter AI — it’s about powering it. And this new technology is quietly b...True Market Insiders | SponsoredJuly 2025 Rule Change to Impact Retirement InvestorsThere's a massive change from a new rule going into effect this July. And it's one the Big Banks are alread...Premier Gold Co | SponsoredEveryone’s watching Nvidia right now. Here’s why I’m excited.So, unless you’ve been living under a rock, you probably saw the news… Nvidia just signed a $7 BILLION deal...Timothy Sykes | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding BioVie Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share BioVie With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Buy BIVI Stock Free BIVI Stock Alerts